Analysis

Protara Therapeutics, Inc. (TARA) Stock Analysis

Protara Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to TARA.

websiteTARA/analysis/TARA

Protara Therapeutics, Inc.

Protara Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to TARA.

Stock profile

Ticker

TARA

Asset type

Stock

Market cap

$223.7M

Sector

Health Technology

Industry

Pharmaceuticals: Major

Currency

USD

Ticker listings

Protara Therapeutics, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • TARA primary listing
  • A2P4JE
  • 1KPA

Latest Protara Therapeutics, Inc. news

Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company committed to advancing transformative therapies for ...

Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026

Event will provide an overview of Lymphatic Malformations, the treatment landscape and the TARA-002 clinical program NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- Protara Therapeut...

Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of t...

TARA-002 demonstrates 72% complete response rate at any time, 67% complete response rate at the 6-month landmark and 55% complete response rate at the 12-month landmark in BCG-N...

Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business

Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients ...

NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company developing transformative therapies for the treatm...

Research sections

Valuation

Review valuation context for Protara Therapeutics, Inc..

Future growth

Review future growth context for Protara Therapeutics, Inc..

Past performance

Review past performance context for Protara Therapeutics, Inc..

Financial health

Review financial health context for Protara Therapeutics, Inc..

Dividend

Review dividend context for Protara Therapeutics, Inc..

Management

Review management context for Protara Therapeutics, Inc..

Ownership

Review ownership context for Protara Therapeutics, Inc..

Other information

Review other information context for Protara Therapeutics, Inc..

Community

Review community context for Protara Therapeutics, Inc..